• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, May 11, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

New MIT research forecasts effect of two-dose vaccine allocation strategies on cumulative number of infections and death in US

Bioengineer by Bioengineer
August 15, 2022
in Health
Reading Time: 5 mins read
0
Two dose vaccine allocation strategies
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New MIT research forecasts the effect of various two-dose vaccine allocation strategies on the cumulative number of infections and deaths in the U.S.—quantifying the impact of prioritizing first versus second doses. The forecasts suggest that allocating more than 50% of available doses to individuals who have not received their first dose can significantly increase the number of lives saved and significantly reduce the number of COVID-19 infections.

With more than 44.7 million infections in the U.S. and 219 million worldwide—and a death toll over 721,000 in the U.S. and 4.55 million worldwide—the COVID-19 pandemic profoundly altered the research agenda of the scientific community. Mass vaccination is now seen as the critical pathway to alleviate the impact of the disease; however, producing and distributing the vaccines has become a substantial challenge for manufacturers. With the emergence of COVID-19 variants—and now with the monkeypox virus recently declared a public health emergency in the U.S.—determining how to effectively allocate vaccines is more critical than ever.

The researchers—Zied Ben Chaouch, PhD candidate, MIT Department of Electrical Engineering and Computer Science; Andrew W. Lo, the Charles E. and Susan T. Harris Professor of Finance at MIT Sloan School of Management; and Chi Heem Wong, research affiliate, MIT Laboratory for Financial Engineering—created a simple epidemiological model that simulates the supply of vaccines and explores how different allocation policies of two-dose vaccines can affect numbers of infections and deaths.

“Two-dose vaccines can be difficult to quickly produce and deliver,” says Ben Chaouch. “This model was applied to the U.S., but it can also be used globally, especially for countries with ongoing supply chain issues.”

The model simulates the supply of vaccine under random shocks, allowing the researchers to gauge the performance of various vaccination policies based on the number of cumulative deaths and cumulative infections. The results shed light on whether it is best to store vaccine doses in order to guarantee a second dose to all individuals who received a first dose, or if it is more efficient to allocate as many first doses as possible.

Storing doses ensures that individuals who received a first dose will be able to obtain their second dose according to the recommended vaccination schedule, even if supply shocks occur. However, this strategy reduces the number of individuals who can be vaccinated each day, and may lead to a higher cumulative number of deaths and infections. (The model assumes that 1% of unused doses are lost each day to reflect spoilage and/or wastage due to unforeseen circumstances.)

The forecasts suggest that, under some mild assumptions, allocating more than 50% of available doses to individuals who have not received their first dose can significantly increase the number of lives saved and significantly reduce the number of COVID-19 infections. The research finds that 50% allocation saves on average 33% more lives, and prevents on average 32% more infections relative to a policy that guarantees a second dose to all first-dose recipients. In fact, in the presence of supply shocks, the incremental benefit of the new policy is 2,184 additional lives saved and 146,357 infections prevented.

While the model was created specifically with COVID-19 in mind, it is intended to be used for addressing other public health crises as well.

“This model provides a practical framework for how to deal with future pandemics,” says Wong.

Two dose vaccine allocation strategies

Credit: Marco Verch aka Wuestenigel: https://linktr.ee/wuestenigel

New MIT research forecasts the effect of various two-dose vaccine allocation strategies on the cumulative number of infections and deaths in the U.S.—quantifying the impact of prioritizing first versus second doses. The forecasts suggest that allocating more than 50% of available doses to individuals who have not received their first dose can significantly increase the number of lives saved and significantly reduce the number of COVID-19 infections.

With more than 44.7 million infections in the U.S. and 219 million worldwide—and a death toll over 721,000 in the U.S. and 4.55 million worldwide—the COVID-19 pandemic profoundly altered the research agenda of the scientific community. Mass vaccination is now seen as the critical pathway to alleviate the impact of the disease; however, producing and distributing the vaccines has become a substantial challenge for manufacturers. With the emergence of COVID-19 variants—and now with the monkeypox virus recently declared a public health emergency in the U.S.—determining how to effectively allocate vaccines is more critical than ever.

The researchers—Zied Ben Chaouch, PhD candidate, MIT Department of Electrical Engineering and Computer Science; Andrew W. Lo, the Charles E. and Susan T. Harris Professor of Finance at MIT Sloan School of Management; and Chi Heem Wong, research affiliate, MIT Laboratory for Financial Engineering—created a simple epidemiological model that simulates the supply of vaccines and explores how different allocation policies of two-dose vaccines can affect numbers of infections and deaths.

“Two-dose vaccines can be difficult to quickly produce and deliver,” says Ben Chaouch. “This model was applied to the U.S., but it can also be used globally, especially for countries with ongoing supply chain issues.”

The model simulates the supply of vaccine under random shocks, allowing the researchers to gauge the performance of various vaccination policies based on the number of cumulative deaths and cumulative infections. The results shed light on whether it is best to store vaccine doses in order to guarantee a second dose to all individuals who received a first dose, or if it is more efficient to allocate as many first doses as possible.

Storing doses ensures that individuals who received a first dose will be able to obtain their second dose according to the recommended vaccination schedule, even if supply shocks occur. However, this strategy reduces the number of individuals who can be vaccinated each day, and may lead to a higher cumulative number of deaths and infections. (The model assumes that 1% of unused doses are lost each day to reflect spoilage and/or wastage due to unforeseen circumstances.)

The forecasts suggest that, under some mild assumptions, allocating more than 50% of available doses to individuals who have not received their first dose can significantly increase the number of lives saved and significantly reduce the number of COVID-19 infections. The research finds that 50% allocation saves on average 33% more lives, and prevents on average 32% more infections relative to a policy that guarantees a second dose to all first-dose recipients. In fact, in the presence of supply shocks, the incremental benefit of the new policy is 2,184 additional lives saved and 146,357 infections prevented.

While the model was created specifically with COVID-19 in mind, it is intended to be used for addressing other public health crises as well.

“This model provides a practical framework for how to deal with future pandemics,” says Wong.

“We recognize that each situation offers its own unique challenges,” added Lo. “The purpose of this tool is to let policymakers get answers to the most relevant questions in the early phases of a pandemic in order to make tough decisions before the point of no return.”



Journal

PLOS Global Public Health

DOI

10.1371/journal.pgph.0000498

Method of Research

Experimental study

Subject of Research

People

Article Title

Should we allocate more COVID-19 vaccine doses to non-vaccinated individuals?

Article Publication Date

1-Jul-2022

Share12Tweet8Share2ShareShareShare2

Related Posts

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

May 11, 2026

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

May 10, 2026

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

May 10, 2026

Urdu Fall Risk Questionnaire Adapted for Elderly

May 10, 2026

POPULAR NEWS

  • Research Indicates Potential Connection Between Prenatal Medication Exposure and Elevated Autism Risk

    840 shares
    Share 336 Tweet 210
  • New Study Reveals Plants Can Detect the Sound of Rain

    727 shares
    Share 290 Tweet 181
  • Salmonella Haem Blocks Macrophages, Boosts Infection

    61 shares
    Share 24 Tweet 15
  • Breastmilk Balances E. coli and Beneficial Bacteria in Infant Gut Microbiomes

    57 shares
    Share 23 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

New Post-Hoc Analysis Explores Daily Oral Orforglipron Use in Adults Over 65 with Obesity, Regardless of Diabetes Status

Evaluating Digoxin Use in Patients with Symptomatic Rheumatic Heart Disease

Evaluating the Effectiveness and Safety of Digitalis Glycosides in Treating Heart Failure

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.